



MARKET RELEASE

19 February 2016

OBJ LIMITED

TRADING HALT

The securities of OBJ Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Tuesday, 23 February 2016 or when the announcement is released to the market.

Security Code: OBJ

Frieda Orr

ADVISER, LISTINGS COMPLIANCE (PERTH)



19 February 2016

Ms Frieda Orr
Adviser, Issuers (Perth)
Australian Securities Exchange
PERTH WA 6000

Dear Frieda,

OBJ Limited (OBJ) – Request for Trading Halt


OBJ Limited (ACN 056 482 636) (ASX: OBJ) (**Company**) hereby requests a trading halt on its securities, effective immediately pending an announcement in relation to the receipt of results from the University of Queensland on the BodyGuard clinical trial.

The Company provides the following information in relation to ASX Listing Rule 17.1:

- the request is made pending the release of an announcement to the market in relation to the results of the clinical trial on the BodyGuard project;
- the Company requests that the trading halt end on the earlier of the commencement of normal trading on Tuesday, 23 February 2016 or when the anticipated announcement referred to above is released;
- the Company is not aware of any reason why the trading halt should not be granted; and
- the Company is not aware of any other information that is necessary to inform the market about the trading halt.

If you have any queries, please do not hesitate to contact me,

Yours faithfully,



JOHN J PALERMO
Company Secretary

transdermal drug delivery technology

ABN 72 056 482 636
284 Oxford Street, Leederville 6007 Perth, Western Australia
Telephone +61 8 9443 3011 Facsimile +61 8 9443 9960 www.obj.com.au